Moving Beyond Price-Per-Dose in the Pharmaceutical Industry

//, Viewpoints/Moving Beyond Price-Per-Dose in the Pharmaceutical Industry

Moving Beyond Price-Per-Dose in the Pharmaceutical Industry

2017-07-03T23:25:00+00:00 September 30th, 2015|Publications, Viewpoints|

Many patients today are missing out on the benefits of therapies for financial reasons. The problem here is our current model of pharmaceutical pricing, which threatens to deprive patients of current beneficial therapies and other breakthroughs to come. For decades, the vast majority of drug manufacturers and payers have relied on pricing per dose, be it a pill, a milligram, or the like. While simple and convenient, the “price-per-dose” (PPD) model produces a number of well-known side effects that are now becoming increasingly severe.

Source: Health Affairs Blog